Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Head and neck cancer management in the Covid-19 era: Our experience

Paola Bonavolonta a,*, Giovanni Dell’Aversana Orabona a, Alfonso Sorrentino a, Vincenzo Abbate a, Federica Goglia a, Piombino Pasqualeb, Giorgio Iaconettab, Luigi Califano a

a Maxillofacial Surgery Unit, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Via Pansini 5, 80100, Naples, Italy
b Neurosurgery Unit, Department of Medicine, Surgery and Odontoiatrics, University of Salerno, Via Giovanni Paolo II 132, 84084, Fisciano, Salerno, Italy

ARTICLE INFO

Keywords:
Covid 19
Head and neck cancer management

ABSTRACT

Introduction: In March 2020 a new viral pandemic was declared. As etiological factor a virus belonging to the coronavirus family was isolated. This virus was named SARS-CoV-2 or COVID-19. This virus can cause different clinical frames, varying from mild symptomatology to cases of ARDS or death. Although the pandemic outbreak in China, COVID-19 had one of first hotspots in Italy, where the Public Health System needed a re-arrangement to face the disease. The incidence of oncological disease doesn’t suffer any variation in relation to pandemics or emergency period, but need to be managed as soon as possible in every situation. In our maxillo-facial surgery Unit we continued our regular activities to treat all oncological patient that needed surgery during the pandemic. Because of the absence of knowledge about the COVID-19, first periods were very difficult to manage, due to the risk of infection of patients and health professionals. We decided to share our experience.

Materials and methods: Between March and June 2020, 34 patients affected by head and neck cancer were admitted at our Unit. All patients underwent surgical treatment and were hospitalized until their situation guaranteed a safe discharge.

Results: All patients treated for head and neck cancer underwent surgery. All the medical and nurse post-operative management was performed by health operators by using all the personal protective equipment (PPE) to prevent any possible infection. All contacts between patients and their family were suspended.

During phase 1, all patients were submitted to a short verbal triage, measurements of physiological parameters and qualitative COVID-19 test. They were also screened by imaging to guarantee there were not any broncho-pulmonary diseases referable to viral infections. During phase 2, patients were also screened by serological tests. During phase 3, all patients practiced oropharyngeal swap before being hospitalized.

Discussion: During lockdown a re-arrangement of the management of oncological patients was mandatory. The difficulties were caused by the restriction of several activities that guarantee a normal health care system function. To date there is not a standardized therapeutic protocol to face the infection. Main therapies are symptomatic and a lot of patients need to be treated in ICUs. To prevent any possible infections, surgical activities were reserved only for urgent disease that cannot be delayed. In our Unit we continued to manage oncological patients. Social distancing and confinement measures were necessary and mandatory, in order to manage our patients. During first phases we had not any valid instrument to totally exclude COVID-19 infection. During phase 3, when oropharyngeal swaps were introduced in the screening of our patients, we could start to work in a safer way.

Conclusion: There are still a lot of difficulties in the management of patients during COVID 19 pandemic. Because of the important consequences deriving from the delay of oncological patients their management must to be clearly defined.

1. Introduction

On 11th of March 2020 the World Health Organization declared COVID-19 a global pandemic [1]. An outbreak of pneumonia cases of unknown etiology was reported for the first time on 31st of December 2019 in China, in the City of Wuhan, Hubei District [2].

On 9th of January 2020, the Chinese CDC recognized the new coronavirus belonging to the SARS-CoV family, as the causative agent of the epidemic. Virus-associated disease is defined as new coronavirus disease...
2019 (COVID-19) [3].
SARS-CoV-2 belongs to the same family of viruses that causes Acute Severe Respiratory Syndrome (SARS) [4].
Starting from February 2020 the diffusion of the virus also extended to Europe. One of the main areas of the contagion until May 2020 is located in Lombardy Region in Northern Italy [5].
To date, the symptoms reported in patients with SARS-CoV-2 infection mainly include fever, cough, dyspnea, myalgia, asthenia. More severe cases develop severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), sepsis and septic shock which can lead to death.
Human infections with common coronaviruses are mostly mild and asymptomatic, but serious and fatal infections have been observed. This evolution is more frequent in immunocompromised people, and in patients affected by cardiopulmonary diseases.
The incubation period for COVID-19 (i.e. the time between exposure to the virus and the onset of symptoms) is currently estimated to be between 2 and 14 days [6-9].
The transmission takes place through respiratory secretions, aerosol and droplets. Nosocomial transmission has been described as an important factor in the epidemiology of SARS [10].
Italian data updated to 21st October 2020 show that 449,648 people contracted the virus, with a total of 36,832 deaths for COVID-19 [11].
The emergency that Italian hospitals have faced has led to a substantial reorganization of hospital activities to avoid the risk of contagion.
In consideration of the urgent provisions concerning the contrast and containment of the diffusion of the COVID-19 virus infection, the Italian Government issued some measures, the DD.PP.CC.MM. of 8.03.2020 and 9.03.2020, in order to standardize any initiatives for the re-organization of hospitalization and outpatient activities. This was necessary to front the potential increase of hospital places reserved for COVID-patients in all care-facilities through the national territory [12].
The DD.PP.CC.MM previewed to stop any elective medical performance, reserving hospital places for urgent and unavoidable diseases.
Elective oncolgical hospitalizations were guaranteed by the Italian National Health System.
For these reasons, according to national measures, during all lockdown period, in our Maxillo-Facial Surgery Unit we treated all patients that presented oncological and traumatic diseases.
There are about 9300 new cases and 3216 deaths every year [13].
Among head and neck cancer, oral cancer is one of the most common malignancies of the face [14,15].
The main therapeutic strategy for these tumors is still represented by surgery [16].
COVID-19 pandemic represents a difficult period to manage these patients, due to the delayed time that it caused in diagnostic and therapeutic strategies.
Although some studies suggested the possibility to suspend surgery for some cases of cancer, in our Unit we decided to always use surgery as first therapeutic choice [17].
Hospital activities continued regularly, but some precautionary measures were introduced, in order to protect the health of healthcare professionals and patients.
The aim of this work is to present our experience in the treatment of oral cancer during the COVID-19 period.

2. Material and methods
In the period between the 1st of March 2020 and the 1st of June 2020 (during the Italian Lockdown), we admitted 34 patients affected by head and neck cancer in the Maxillofacial Surgery Unit of Federico II University of Naples.
All patients underwent surgery.
Preliminary hospitalization procedures consist in the execution of qualitative test and chest x-rays. The importance of lung instrumental images has been widely documented in Literature [20].

During Phase 2, we continued to adopt the same procedures for outpatients. While, as regards the hospitalized patients, they were also subjected to the serological test, for the specific quantitative dosage of the antibodies.

In Phase 3, all hospitalized patients have been previously screened by a oropharyngeal. Particular attention was attributed to social distancing. All people inside our Unit were provided with individual protection devices.

Our hospital provided a limitation of the number of patients for each room. Socialization between patients was not allowed, and they were obliged to wear a mask when they were not in their rooms.

With regards to personal protective devices, each health care worker was obliged to wear always FFP2 (KN95) masks, single use gloves and also an eye-shields.

4. Discussion

Coronaviruses (CoV family) are RNA viruses with tropism for respiratory and gastrointestinal tract epithelium cell. The "spill over" of animal to human tropism viruses is considered the mechanism that made origin to SARS-CoV-2.

In order to reduce the risk of spreading new coronavirus infections, it is recommended to promote sanitation; frequent thorough hand washing; avoiding touching the eyes, mouth and nose; sanitary disposal of oral and nasal secretions, avoiding contact with sick patients [21,22].

Strict infection's prevention and control procedures (IPC) are critical for a safe working place and for the control of these pathogens.

The World Health Organization (WHO) recommends that healthcare professionals apply appropriate prevention and control measures. For procedures that generate aerosols, such as tracheal intubation, bronchoalveolar washing and manual ventilation, the use of PPE is recommended.

While during the first period there were no recommended therapies to treat the Covid-19 infection, today there are some therapeutic protocols, nevertheless still not approved by the World Health Organization (WHO).

The systematic implementation of public health measures such as the active detection of cases, the rapid isolation of cases and the quarantine of contacts, as well as the rigorous application of infection control practices, have been successful in the control of outbreaks [23].

In our region, since the beginning of the pandemic, we registered a change in the Healthcare management. Regional Government imposed an increase in the places reserved to the treatment of Covid-19. This was possible due to the suspension of any elective hospitalization and operations. Starting from March 2020, until June 2020, public and private hospitals it was possible to hospitalize only patients affected by urgent diseases. In our Maxillo-facial Unit it was only possible to treat traumatological and oncological patients, because of their not deferable clinical status.

During the A-phase (March 2020–May 2020) 92 places were reserved to Covid-19 infected patients in the whole Campania Region. During this phase the Campania region had little incidence of infections due to the important restrictions imposed by the regional government. This number of places has been always increased, during next months, to 1651 during our z-phase, starting from October 2020 [24].

By our analysis lockdown determined a delay in the diagnostic and therapeutic protocols. Patients started to neglect their health status, due to the confinement and the isolation measures set up by the Italian Government. It was really difficult to accede to the family doctors for a preliminary evaluation, because of their priorities to face up patients that presented signs to refer to a coronavirus infection. Oncological patients generally delayed their clinical examinations, also troubling for the risk to be infected. When they finally were addressed to specialist consulting in our Unit, they were founded to be in an advanced TNM stage.

5. Conclusion

With this editorial we want to share our experience in managing the treatment of patients with head and neck cancers, in this difficult pandemic period that we are facing.

Considering that the incidence of head and neck cancer does not undergo variation depending on this period, due to independent etiological factors, oncological patients need to receive their surgical treatment without any delay. To date there are still many difficulties related to the management of oncological patients during this pandemic, so our hospitalization protocol may furnish an instrument in helping to define clearer guidelines.

Ethics statement/confirmation of patient permission

Yes.

Declaration of competing interest

No.

References

[1] https://www.jvwatch.org/vol1644/2020/03/11/who-declares-10-covid-19-pandemic-2020. Accessed April 24.

[2] Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med 2020 Feb 28;382(8):994–4. https://doi.org/10.1056/NEJMmp2000929. Epub 2020 Jan 24. PMID: 31972639.

[3] Zha n, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, r, n iu, Zhan F, Ma X, Wang D, Xu W, Wu g, gao g, f, tan W. China noVeCoronaVirus inVestigating a nd researCh teaM. A novel coronavirus from patients withpneumonia in China. N Engl J Med 2019. 2020 Jan 24.

[4] Zhou p, Yang Xl, Wang Xg, hu B, Zhang L, Zhang W. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. Nature 2020.

[5] Saibene AM, Allefi F, Biglioti F, Felsiani G. Role and management of a head and neck department during the COVID-19 outbreak in Lombardy. Otolaryngol Head Neck Surg 2020 Jan;162(1):795–6. https://doi.org/10.1177/0149591820917914. Epub 2020 Apr 7. PMID: 32259735.

[6] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020 Apr;92(4):401–2. https://doi.org/10.1002/jmv.25678. Epub 2020 Feb 12. PMID: 31950516; PMCID: PMC7166628.

[7] Nishiura H, Jung SM, Linton NM, Kinoshita R, Yang Y, Hayashi K, Kobayashi T, Yuan B, Akmetshitev AR. The extent of transmission of novel coronavirus in Wuhan, China. 2020 J Clin Med 2020 Jan; 9(2):323. https://doi.org/10.3390/jcm9020323. PMID: 31991628; PMCID: PMC7073674.

[8] Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92(4):418–23. https://doi.org/10.1002/jmv.25681. Epub 2020 Feb 7. Erratum in: J Med Virol 2020 Aug 2;: 31967327; PMCID: PMC7167049.

[9] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsui HW, Lo SK, Chan KH, Poon VY, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395(10223):514–23. https://doi.org/10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24. PMID: 31986261; PMCID: PMC7159286.

[10] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020 Mar 13;7(1):11. https://doi.org/10.1186/s40779-020-00240-0. PMID: 32169119; PMCID: PMC7068984.

[11] https://www.epicentro.iss.it/coronavirus/bollettino.

[12] https://www.gazzettaufficiale.it.

[13] AOIM. AIBTM. I numeri del cancro in Italia. Il Pensiero Scientifico; 2019. 2019.

[14] Ricciardi C, Sorrentino A, Impriota G, Abbate V, Latessa I, Perrone A, Triassi M, Dell'aversana Orabona G. A health technology assessment between two pharmacological therapies through Six Sigma: the case study of bone cancer. TQM J 2020;32(6):1507–24.

[15] Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008 Apr;83(4):489–501. https://doi.org/10.4065/83.4.489. Ersaturn in: Mayo Clin Proc. 2008 May;83(5):504. PMID: 18388996.

[16] Brody RM, Alibergotti WG, Shimunov D, Nicollini E, Patel UA, Harris BN, Bur AM. Changes in head and neck oncologic practice during the COVID-19 pandemic. Head Neck 2020 Jul;42(7):1448–53. https://doi.org/10.1002/hed.26233. Epub 2020 Jun 11. PMID: 32357380; PMCID: PMC7267666.
[17] Wu V, Noel CW, Forner D, Zhang ZJ, Higgins KM, Enepekides DJ, Lee JM, Witterick IJ, Kim JJ, Waldron JW, Irish JC, Hua QQ, Eskander A. Considerations for head and neck oncology practices during the coronavirus disease 2019 (COVID-19) pandemic: Wuhan and Toronto experience. Head Neck 2020 Jun;42(6):1202–8.

[18] Mehanna H, Hardman JC, Shenson JA, et al. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet Oncol 2020;21(7):e350–9.

[19] Ansarin M. Surgical management of head and neck tumours during the SARS-CoV (COVID-19) pandemic. Acta Otorhinolaryngol Ital 2020;40(2):87–9.

[20] Sun Z, Zhang N, Li Y, Xu X. A systematic review of chest imaging findings in COVID-19. Quant Imag Med Surg 2020;10(5):1058–79. https://doi.org/10.21037/qims-20-564.

[21] Barca I, Cordaro R, Kallaverja E, Ferragina F, Cristofaro MG. Management in oral and maxillofacial surgery during the COVID-19 pandemic: our experience. Br J Oral Maxillofac Surg 2020;58(6):687–91.

[22] Valentini V, Pucci R, Battisti A, Cassoni A. Head and neck cancer cannot wait for this pandemic to end: risks, challenges and perspectives of oral-maxillofacial surgeon during COVID-19. Oral Oncol 2020 Jul;106:104758. https://doi.org/10.1016/j.oraloncology.2020.104758. Epub 2020 May 1. PMID: 32389540; PMCID: PMC7252117.

[23] Liu X, Liu C, Liu G, Lao W, Xia N. COVID-19: progress in diagnostics, therapy and vaccination. Theranostics 2020;10(17):7821–35. https://doi.org/10.7150/thno.47987. Published 2020 Jun 19.

[24] https://www.regione.campania.it/assets/documents/raccomandazioni-operative-per-la-gestione-e-contenimento-da-infezione-covid-19.pdf.